Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.54 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400005 | 0.92 | MAPK14 (0.55) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL1399817 | 0.91 | MAPK14 (0.55) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL1399820 | 0.90 | MAPK14 (0.57) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL1399765 | 0.90 | MAPK14 (0.56) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL1399786 | 0.90 | MAPK14 (0.52) | MAPK14 | |
| SCHEMBL1399998 | 0.90 | MAPK14 (0.54) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL1399851 | 0.89 | MAPK14 (0.51) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL1399838 | 0.89 | MAPK14 (0.53) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 | |
| SCHEMBL1399868 | 0.88 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL1399927 | 0.88 | MAPK14 (0.52) | MAPK14RPS6KA5CYP3A4MAPKAPK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831174-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7786115-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-08-31 | — | — | US | disclosed |
| US-20080146566-A1 | Amide Derivatives | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146566-A1 | Amide Derivatives | IL6, IL1B, IL1A | MAPK14 2077/4885RPS6KA5 685/4885CYP3A4 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.